Fatal toxicity associated with antidepressant use in primary care

Authors: Mason J.; Freemantle N.; Eccles M.

Source: British Journal of General Practice, Volume 50, Number 454, May 2000 , pp. 366-370(5)

Publisher: Royal College of General Practitioners

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background. New selective serotonin reuptake inhibitors (SSRIs) are perceived to be much safer in use than older tricyclic antidepressants (TCAs). However, previous assessments of association with fatal toxicity were made too soon after the introduction of the new drugs to permit accurate estimation.

Aim. To determine the level of association of antidepressant drugs with fatal poisoning in the treatment of depression.

Method. National data for England and Wales for three years (1993 to 1995) for fatal poisonings associated with antidepressants were obtained and, together with national primary care data on prescribing, were used to calculate fatality association by antidepressant drug.

Results. There were substantial variations between drugs in the level of association with fatal poisoning. Assuming an average treatment episode lasted three months, one fatality is associated with 11 800 treatment episodes of antidepressant use (95% CI = 11 120 to 12 580) when only single substance fatalities are considered. For SSRIs as a group the association was one in 411 800 (95% CI = 243 300 to 1.34 million) and for TCAs one in 8130 (95% CI = 7650 to 8670). However, for one of the newer TCAs, lofepramine, the single substance fatality rate associated with its use was one in 233 700 (95% CI = 124 500 to 1.89 million), which is not statistically significantly different from the SSRIs (P = 0.35).

Conclusions. Estimated death rates associated with specific antidepressants should be compared with caution because drugs may be used selectively in patients with differing severity of depression. The proportion of these fatalities that could be prevented by switching to safer antidepressants is unclear when so few deaths are recorded as accidental; when there is intent to do self-harm the potential for switching to other means is unknown. However, this approach to relative toxicity may remain the best available since it is unlikely that a randomised trial will ever be conducted with a large enough sample size to obtain experimental data. Fatalities from antidepressant poisoning are very rare but if safety is paramount then lofepramine or an SSRI are justifiable treatment choices.

Keywords: MENTAL HEALTH; ANTIDEPRESSANTS; FATAL TOXICITY; SSRIS; TCAS

Document Type: Research article

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$31.30 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A